ACW September 2026 quarterly activity report & Appendix 4C
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The report highlights strong enrolment in the open-label extension phase of the XanaMIA trial, with a high percentage of participants opting to continue treatment. Financially, the company reported a cash balance that supports operations into the following years, bolstered by recent funding from option exercises. The report also outlines ongoing commercial planning and new patent grants related to its lead compound, Xanamem, aimed at treating Alzheimer's disease.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
- Underwriting of unlisted options completed
- ACW Alzheimers pivotal trial completes last patient visit
- ACW unlisted options fully underwritten
- ACW FY2026 results and outlook
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical